CSL is one of three Tier 1 plasma therapy companies that benefit from an oligopoly in a highly consolidated market. All the players are vertically integrated as plasma sourcing is a key constraint ...

Pharmaceuticals company CSL on Tuesday reported a 3% rise in first-half profit, benefiting from further growth in its main blood-plasma business.

Takeda’s plasma-derived therapies (PDT) business tackles supply-chain challenges to expand access to life-saving treatments, ...

Pharmaceuticals company CSL on Tuesday reported a 3% rise in first-half profit, benefiting from further growth in its main blood-plasma business. Australia-based CSL, which runs a network of ...

CSL) reported a rise in half-year net profit, driven primarily by robust performance in its blood plasma division. The company's CSL Behring unit, which focuses on plasma-derived therapies ...

The dilapidated and outdated mall is located in a 643-acre Town Center zoning district (TC) around the intersection of Routes 30 and 100, at what is known as the Exton Crossroads. The mall is ...

The CSL Ltd (ASX: CSL) share price hit a 52-week low of $253.95 on Wednesday. Since the end of July 2024, it has dropped close to 20%. Investors may be asking themselves whether this ASX blue-chip ...

Learn More If you have been thinking about buying CSL Ltd (ASX: CSL) shares, then read on. That's because Goldman Sachs has just named another reason to buy the biotechnology giant's shares.

Scientists have developed a method for generating fast, bright proton beams using a high-repetition-rate laser-plasma accelerator. This work, published in Nature Communications, resolves several ...